- Lake Street initiates MiMedx (MDXG.PK) at Buy.
- The company is set to triple revenue for its wound care product EpiFix and double sales of AminoFix, its soft-tissue repair offering, analysts say.
- The company also "has a foundation of strong intellectual property (100+ patents) and is led by an experienced management team with a history of successfully building and selling medical companies."
- Ultimately, Lake Street thinks the company can top $400M in revenue and generate $100M in EBITDA "in the next four to five years."
- Price target is $7.50.
MiMedx to top $400M in revenue by 2018: Lake Street
Aug 20 2013, 08:15 ET